Detection of mutants in polio vaccine viruses using pooled antipoliovirus monoclonal antibodies

Biologicals

Volumn 27, Issue 3, 1999, Pages 217-226

  Horie, Hitoshi ^a   Sato Miyazawa, Miwako ^a   Ota, Yoshihiro ^a   Wakabayashi, Kengo ^a   Doi, Tsugumi ^a   Yoshizawa, Kuniko ^a   Doi, Yutaka ^a   Hashizume, So ^a  

^a Japan Poliomyelitis Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; ORAL POLIOMYELITIS VACCINE;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; DRUG SAFETY; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS MUTANT; VIRUS VIRULENCE;

ANIMALIA; POLIOVIRUS; RNA VIRUSES;

EID: 0033375015     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0211     Document Type: Article

References (28)

1. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand. 1:1973; 115-118.
2. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 151:1985; 420-436.
3. Bull WHO. 60:1982; 231-242.
4. Nkowane BM, Wassilak SGF, Orenstein WA. Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. JAMA. 257:1987; 1335-1340.
5. Holland J, Spindler K, Horodyski F. Rapid evolution of RNA genomes. Science. 215:1982; 1577-1585.
6. Ward CD, Stockes MAM, Flanegan JB. Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol. 62:1988; 558-562.
7. Sabin AB. Present status of attenuated live-virus poliomyelitis vaccine. JAMA. 162:1956; 1589-1596.
8. Nakano M, Matsukura T, Yoshii K. Genetical analysis on the stability of poliovirus type 3 Leon 12a 1 b. J Biol Stand. 7:1979; 157-168.
9. WHO Techn Rep Ser. 800:1990; 30-65.
10. Wood DJ, Macadam AJ. Laboratory tests for live attenuated poliovirus vaccines. Biologicals. 25:1997; 3-15.
11. Kawamura N, Kohara M, Abe S. Determinants in the 5′ non coding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 63:1989; 1302-1309.
12. Christodoulou C, Colber-Garapin F, Macadam A. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol. 64:1990; 4922-4929.
13. Horie H, Koike S, Kurata T. Transgenic mice carrying the human poliovirus receptor: new animal model for study of poliovirus neurovirulence. J Virol. 68:1994; 681-688.
14. Pollard SR, Dunn G, Cammack N. Nucleotide sequence of a neurovirulent variant of the Type 2 oral poliovirus vaccine. J Virol. 63:1989; 4949-4951.
15. Macadam AJ, Pollard SR, Ferguson G. The 5′ noncording region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology. 181:1991; 451-458.
16. Evans DMA, Dunn G, Minor PD. Increased neurovirulence associated with a single nucleotide change in a non-coding region of the Sabin type 3 poliovaccine genome. Nature. 314:1985; 548-550.
17. Westrop GD, Wareham KA, Davis DMA. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 63:1989; 1338-1344.
18. Chumakov KM, Powers LB, Noonan KE. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A. 88:1991; 199-203.
19. Chumakov KM, Norwood LP, Parker ML. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol. 66:1992; 966-970.
20. Chumakov KM, Norwood LP, Parker ML. Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Dev Biol Stand. 78:1993; 79-89.
21. Wood DJ. New approaches to oral poliovirus vaccine neurovirulence tests: transgenic mice susceptible to poliovirus and molecular analysis of poliovirus. Vaccine. 15:1997; 341-345.
22. Horie H, Sato M, Doi Y. The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine. Vaccine. 14:1996; 35-41.
23. Osterhaus ADME, Van Weazel AL, Van Steenis B. Monoclonal antibodies to polioviruses: Production of specific monoclonal antibodies to the Sabin vaccine strains. Intervirology. 16:1981; 218-224.
24. Horie H, Tano Y, Doi Y. Estimation of the neurovirulence of poliovirus molecular analysis to quantify genomic changes. Biologicals. 26:1998; 289-297.
25. Koike S, Taya C, Kurata T. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A. 88:1991; 951-955.
26. Abe S, Ota Y, Koike S. Neurovirulence test for oral live poliovaccine using poliovirus-sensitive transgenic mice. Virology. 206:1995; 1075-1083.
27. Dragunsky E, Taffs R, Chernokhvostova Y. A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine. Biologicals. 24:1996; 77-86.
28. Rezapkin GV, Chumakov KM, Lu Z. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology. 202:1994; 370-378.